Cowen's Line in the Sand
Executive Summary
Cowen's Dan LeMaitre, a leading device analyst, dropped coverage of Boston Scientific claiming that the company wasn't providing sufficient information for accurate valuations. The dispute calls into question an investor relations strategy one executive calls "seriously flawed."